Ally Olotu is a KEMRI-Wellcome Trust affiliate and works with Ifakara Health Institute in Bagamoyo, Tanzania. He has an MD degree from the University of Dar es Salaam and a DPhil. in Clinical Epidemiology and vaccinology from the University of Oxford, UK. His interest is in malaria epidemiology and clinical trials that investigate the safety, immunogenicity, and public health utility of interventions in low and middle-income countries (LMICs).
A
Emerging interests include the improvement of the quality of clinical care in public health facilities. In 2005, he received the WHO/TDR Career Development Fellowship in Malaria Vaccine Development at GSK Biologicals in Rixensart, Belgium, and WHO/TDR headquarters in Geneva, Switzerland. His contribution has been to the investigation of the long-term efficacy of RTS,S candidate malaria vaccine in young children living in a malaria endemic country, describing its interaction with malaria exposure and studying the correlates of immune protection in children who received RTS,S vaccine in Kenya.
In 2013 he won the Oxford University Nuffield Department of Medicine Graduate Research Prize for his DPhil work. He also coordinated the first-ever clinical trials in the history of Equatorial Guinea, evaluating the safety and efficacy of Sanaria’s PfSPZ Vaccine.